Cloning and analysis of human UroplakinII promoter and its application for gene therapy in bladder cancer.
- Published in:
- Cancer Gene Therapy, 2004, v. 11, n. 4, p. 263, doi. 10.1038/sj.cgt.7700672
- By:
- Publication type:
- Article
Works matching IS 09291903 AND DT 2004 AND VI 11 AND IP 4
Results: 8
1
2
Adenoviral-mediated PTEN transgene expression sensitizes Bcl-2-expressing prostate cancer cells to radiation.
- Published in:
- Cancer Gene Therapy, 2004, v. 11, n. 4, p. 273, doi. 10.1038/sj.cgt.7700673
- By:
- Publication type:
- Article
3
Synergistic antitumor effect by coexpression of chemokine CCL21/SLC and costimulatory molecule LIGHT.
- Published in:
- Cancer Gene Therapy, 2004, v. 11, n. 4, p. 280, doi. 10.1038/sj.cgt.7700676
- By:
- Publication type:
- Article
4
Transcriptional targeting of tumors with a novel tumor-specific survivin promoter.
- Published in:
- Cancer Gene Therapy, 2004, v. 11, n. 4, p. 256, doi. 10.1038/sj.cgt.7700679
- By:
- Publication type:
- Article
5
Gene therapy for esophageal carcinoma: the use of an explant model to test adenoviral vectors ex vivo.
- Published in:
- Cancer Gene Therapy, 2004, v. 11, n. 4, p. 289, doi. 10.1038/sj.cgt.7700680
- By:
- Publication type:
- Article
6
GSH depletion enhances adenoviral bax-induced apoptosis in lung cancer cells.
- Published in:
- Cancer Gene Therapy, 2004, v. 11, n. 4, p. 249, doi. 10.1038/sj.cgt.7700684
- By:
- Publication type:
- Article
7
Carcinoembryonic antigen-immunoglobulin Fc fusion protein (CEA-Fc) for identification and activation of anti-CEA immunoglobulin-T-cell receptor-modified T cells, representative of a new class of Ig fusion proteins.
- Published in:
- Cancer Gene Therapy, 2004, v. 11, n. 4, p. 297, doi. 10.1038/sj.cgt.7700685
- By:
- Publication type:
- Article
8
In vivo rejection of tumor cells dependent on CD8 cells that kill independently of perforin and FasL.
- Published in:
- 2004
- By:
- Publication type:
- Correction Notice